Survodutide: Boehringer's Dual Agonist Progress

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Retatrutide is a triple agonist that showed significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes Lilly's Retatrutide Phase 3 Trial Results.
Orforglipron, an oral GLP-1, helped participants maintain weight loss after switching from injectable incretins, with an average of 0.9 kg maintained from Wegovy Orforglipron Weight Maintenance Study.
Orforglipron delivered an average weight loss of up to 27.3 lbs in one Phase 3 trial for adults with obesity Orforglipron Obesity Treatment Clinical Trial.
Lilly has submitted orforglipron to the U.S. Food and Drug Administration for the treatment of obesity.

Eli Lilly and Company is developing new medications in the GLP-1 class, focusing on both injectable and oral options to help people manage weight and type 2 diabetes. These include retatrutide, a triple agonist, and orforglipron, an oral GLP-1 receptor agonist. Retatrutide has already shown significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes. Orforglipron, an oral pill, has demonstrated impressive weight loss results, with participants losing up to an average of 27.3 lbs in one Phase 3 trial. It also helped individuals maintain weight loss when switching from injectable treatments like Wegovy, with an average of 0.9 kg of weight loss maintained. These new treatments aim to offer more choices and potentially greater effectiveness for those needing help with obesity and diabetes management.

What is Retatrutide?

Retatrutide, known by its study code LY3437943, is an investigational medication developed by Eli Lilly. It represents a new approach in the treatment of obesity and type 2 diabetes because it is a "triple agonist." This means it works on three different receptors in the body, which could lead to more powerful effects compared to current medications that target one or two receptors. The medication is currently being studied in clinical trials to understand its full potential and safety.

How Triple Agonists Work

Traditional GLP-1 medications, like semaglutide (Wegovy, Ozempic), target the GLP-1 receptor. Newer dual agonists, like tirzepatide (Zepbound, Mounjaro), target both GLP-1 and GIP receptors. Retatrutide goes a step further by activating three different incretin hormone receptors: GLP-1, GIP, and glucagon receptors. This multi-target action is designed to enhance the body's natural systems for controlling blood sugar and appetite. By influencing these multiple pathways, retatrutide aims to provide more comprehensive benefits for both weight loss and blood sugar management. The goal is to maximize the therapeutic effects, leading to better outcomes for patients.

Retatrutide for Obesity and Overweight

Lilly is actively studying retatrutide in participants who have obesity or are overweight. Clinical trials are crucial for gathering data on how well the drug works and if it is safe for widespread use. These studies involve many participants and track their progress over time, looking at measures like weight reduction, changes in body composition, and any side effects. This research helps scientists understand the specific benefits retatrutide might offer to people struggling with excess weight. The detailed information about these ongoing studies can be found on public databases like ClinicalTrials.gov, where the study NCT05929066 outlines a trial of retatrutide in participants with obesity or overweight.

Retatrutide for Type 2 Diabetes

Beyond weight management, retatrutide is also being investigated for its role in treating type 2 diabetes. The triple agonist mechanism is particularly promising for diabetes because it can help improve insulin sensitivity, reduce glucose production by the liver, and slow down stomach emptying. All these actions contribute to better blood sugar control, which is a primary goal in diabetes treatment. The comprehensive approach of targeting three receptors could potentially offer superior control of A1C levels, a key indicator of long-term blood sugar management, compared to existing treatments.

How has Retatrutide performed in trials?

Retatrutide has shown promising results in its early clinical trials, particularly for people with type 2 diabetes. Its unique triple agonist mechanism appears to deliver significant benefits, according to the data released by Lilly. These initial findings are a crucial step in the drug's development, indicating its potential to become an important new treatment option.

Early Phase 3 Trial Results for Type 2 Diabetes

In its first Phase 3 trial specifically designed for the treatment of type 2 diabetes, retatrutide demonstrated significant reductions in A1C and weight Lilly's Retatrutide Phase 3 Trial Results. These are critical outcomes for individuals living with type 2 diabetes, as managing both blood sugar and weight can be challenging. A significant reduction in A1C indicates improved long-term blood sugar control, which helps prevent diabetes-related complications. The concurrent weight reduction is also highly beneficial, as excess weight often worsens insulin resistance and makes diabetes harder to manage. The trial results suggest that retatrutide's triple action is effective in addressing these core aspects of the disease.

Ongoing Studies for Obesity and Overweight

While the initial Phase 3 results focused on type 2 diabetes, retatrutide is also undergoing extensive study for its effects on obesity and overweight individuals without diabetes. A detailed study, NCT05929066, is currently listed on ClinicalTrials.gov, focusing on retatrutide (LY3437943) in participants who have obesity or are overweight. This trial is designed to evaluate the drug's efficacy and safety specifically for weight management. Researchers are looking at various measures, including the amount of weight participants lose, improvements in body composition, and how well they tolerate the medication. This ongoing research is vital for understanding the full scope of retatrutide's benefits as a potential weight loss treatment.

Comparing Retatrutide to Other GLP-1s

The triple agonist nature of retatrutide sets it apart from currently approved GLP-1 medications. While drugs like semaglutide (Wegovy) are GLP-1 receptor agonists and tirzepatide (Zepbound) is a dual GLP-1/GIP receptor agonist, retatrutide adds glucagon receptor agonism to the mix. This broader action could theoretically lead to greater weight loss and better metabolic control. The significant reductions in A1C and weight seen in its first Phase 3 trial for type 2 diabetes suggest that this expanded mechanism might indeed be delivering enhanced results. The medical community is keenly watching for more detailed data from these trials to confirm these promising early findings and understand how retatrutide will fit into the evolving landscape of obesity and diabetes treatments.

Future Outlook for Retatrutide

Based on the strong early performance, retatrutide is positioned as a potential breakthrough in the field. Its ability to significantly impact both blood sugar and weight in people with type 2 diabetes, combined with ongoing studies for obesity, indicates a broad therapeutic potential. As more data from the Phase 3 trials become available, a clearer picture of its long-term efficacy, safety profile, and place in clinical practice will emerge. The development of such a potent multi-agonist represents a significant advancement, offering hope for improved outcomes for many patients.

What is Orforglipron?

Orforglipron is another innovative medication from Eli Lilly, but with a key difference: it is an oral small-molecule GLP-1 receptor agonist. This means it can be taken as a pill, offering a convenient alternative to the injectable GLP-1 medications that are currently common. Its development focuses on providing an accessible and effective treatment option for conditions like obesity and type 2 diabetes.

Oral vs. Injectable GLP-1 Medications

Currently, many effective GLP-1 medications, such as semaglutide and tirzepatide, are administered via injection. While highly effective, injections can be a barrier for some patients due to needle aversion or simply the inconvenience. Orforglipron, being an oral pill, aims to overcome these challenges. The convenience of an oral dose can improve patient adherence to treatment, meaning people are more likely to take their medication regularly as prescribed. This ease of use could make a significant difference in how many people can benefit from GLP-1 therapy.

How Orforglipron Works as a GLP-1 Agonist

Like other GLP-1 receptor agonists, orforglipron works by mimicking the action of glucagon-like peptide-1 (GLP-1), a natural hormone in the body. When activated, the GLP-1 receptor helps regulate blood sugar by stimulating insulin release when blood sugar is high, slowing down stomach emptying, and reducing appetite. For orforglipron, being a small-molecule agonist means it can be absorbed effectively when taken orally, unlike peptide-based GLP-1s that would be broken down in the digestive system. This oral formulation allows for once-daily administration, simplifying the treatment regimen for patients. A study on Orforglipron for obesity treatment was published in N Engl J Med. 2025 Nov 6, highlighting its significance (PMID: 40960239).

Development by Eli Lilly

Eli Lilly and Company has been at the forefront of developing GLP-1 and related incretin-based therapies. Orforglipron is part of their extensive pipeline aimed at addressing the growing global health challenges of obesity and type 2 diabetes. The company's investment in an oral small-molecule GLP-1 demonstrates a commitment to expanding treatment options and improving patient access. This drug is designed to offer a similar level of efficacy to injectable GLP-1s but in a more patient-friendly format, potentially transforming how these conditions are managed in the future.

Orforglipron's Role in the Future of Treatment

The introduction of an effective oral GLP-1 like orforglipron could significantly change the treatment landscape. For many, a daily pill is easier to incorporate into their routine than weekly injections. This increased convenience could lead to broader adoption of GLP-1 therapies, helping more people achieve their weight loss and blood sugar management goals. As research continues, the full impact of orforglipron on patient care and public health will become clearer.

How effective is Orforglipron for weight loss?

Orforglipron has shown impressive effectiveness in promoting weight loss during its Phase 3 clinical trials. The data indicates that this oral medication can lead to significant reductions in body weight, comparable to what has been observed with some injectable GLP-1 therapies. These results are particularly exciting because orforglipron offers the convenience of a pill.

Significant Weight Loss in Phase 3 Trials

In one pivotal Phase 3 trial, orforglipron delivered weight loss of up to an average of 27.3 lbs in adults with obesity Orforglipron Obesity Treatment Clinical Trial. This level of weight reduction is substantial and represents a significant improvement for many individuals struggling with obesity. The trial results demonstrate the drug's potent effect on body weight, making it a strong contender in the obesity treatment market. Achieving such results with an oral medication is a major step forward, as it could make effective weight loss therapy more accessible to a wider population.

Maintaining Weight Loss After Switching from Injectables

One of the unique aspects of orforglipron's performance is its ability to help people maintain weight loss after transitioning from injectable incretin therapies. In the first-of-its-kind ATTAIN-MAINTAIN Phase 3 trial, participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average Orforglipron Weight Maintenance Study. This is a crucial finding because it addresses a common challenge in weight management: sustaining the weight loss achieved with initial treatments. The ability to switch from an injectable to an oral medication without significant weight regain offers flexibility and long-term viability for patients. This means that individuals who start with an injectable GLP-1 could potentially transition to an oral option like orforglipron for continued maintenance, which could improve their overall treatment experience and adherence.

Efficacy for Type 2 Diabetes

Beyond weight loss, orforglipron has also demonstrated statistically significant efficacy results for type 2 diabetes. While the specific A1C reduction figures are not detailed in the provided research, the successful Phase 3 trial confirmed its ability to manage blood sugar levels effectively. This dual benefit—significant weight loss and improved glycemic control—makes orforglipron a valuable option for people living with both obesity and type 2 diabetes. The consistency of its safety profile with injectable GLP-1 medicines further supports its potential as a comprehensive treatment.

Regulatory Submission for Obesity Treatment

Given these strong results, Lilly has taken the next step by submitting orforglipron to the U.S. Food and Drug Administration (FDA) for the treatment of obesity. This submission marks a critical milestone, moving the drug closer to potential approval and availability for patients. The FDA review process will rigorously evaluate all the clinical trial data to ensure the medication is both safe and effective for its intended use. If approved, orforglipron would offer a new, convenient oral option for managing obesity, potentially expanding access to effective treatment for many.

Is Orforglipron's safety profile consistent with other GLP-1s?

Yes, Orforglipron has shown a safety profile that is consistent with injectable GLP-1 medicines. This consistency was observed during its successful Phase 3 trials. This is an important finding because it suggests that while Orforglipron offers the convenience of an oral pill, it does not introduce new or unexpected safety concerns compared to the established injectable GLP-1 treatments already on the market.

Understanding the Safety Profile

When new medications are developed, a major part of the clinical trial process involves thoroughly assessing their safety. This includes monitoring for adverse events, which are any unfavorable changes in a participant's health during a study. For GLP-1 medications, common side effects often involve the gastrointestinal system, such as nausea, vomiting, diarrhea, and constipation. The fact that Orforglipron's safety profile is consistent with injectable GLP-1s indicates that the types and frequency of these side effects are generally similar to what patients experience with existing treatments. This predictability helps both patients and healthcare providers understand what to expect when starting Orforglipron.

Data from Successful Phase 3 Trials

The consistent safety profile was demonstrated in multiple successful Phase 3 trials for Orforglipron. These trials involved a large number of participants, allowing researchers to collect comprehensive data on both the efficacy and safety of the drug. The robust nature of Phase 3 studies means that the findings are reliable and provide a solid basis for evaluating the medication's overall risk-benefit balance. Observing a safety profile consistent with injectable GLP-1s in these advanced trials builds confidence in Orforglipron as a viable treatment option.

Implications for Patient Acceptance

A consistent safety profile is critical for patient acceptance and widespread adoption of a new medication. If a new drug offers a significant advantage, like being an oral pill, but comes with a drastically different or more severe set of side effects, it might limit its use. However, by maintaining a similar safety profile to familiar injectable GLP-1s, Orforglipron can be integrated more smoothly into existing treatment paradigms. Patients and doctors can feel more confident transitioning to or starting with Orforglipron, knowing that the side effect experience will likely be similar to what is already known and managed with other GLP-1 therapies.

Once-Daily Oral Administration

Orforglipron is designed for once-daily oral administration. This dosing schedule is not only convenient but also helps maintain consistent drug levels in the body, which can contribute to both its efficacy and predictable safety. The ability to take a medication once a day by mouth simplifies adherence for patients, potentially leading to better long-term treatment outcomes. The combination of an oral route, once-daily dosing, and a familiar safety profile makes Orforglipron a highly attractive option in the evolving landscape of obesity and diabetes management.

What are the latest developments for Orforglipron?

The development of Orforglipron has reached significant milestones, bringing it closer to potentially becoming a widely available treatment. Eli Lilly has been actively progressing this oral GLP-1 receptor agonist through advanced clinical trials and regulatory processes. These latest developments highlight the drug's potential impact on obesity and diabetes management.

Submission to the U.S. Food and Drug Administration

Lilly has submitted orforglipron to the U.S. Food and Drug Administration (FDA) for the treatment of obesity. This submission is a critical step in the drug development process. It means that Lilly has compiled all the necessary data from its extensive clinical trials, including efficacy and safety information, and presented it to the FDA for review. The FDA will now rigorously evaluate this information to determine if orforglipron meets the standards for approval, ensuring it is both safe and effective for patients with obesity. This move signals Lilly's confidence in the drug's performance and its potential to address a significant public health need.

Success in the ATTAIN-MAINTAIN Trial

One of the key trials supporting the regulatory submission is the ATTAIN-MAINTAIN Phase 3 trial. In this study, orforglipron achieved its primary and all key secondary endpoints for weight maintenance versus placebo at 52 weeks. This trial was particularly innovative as it investigated how well orforglipron could help people maintain weight loss after they had already achieved it on other injectable incretin therapies, such as Wegovy or Zepbound. The success of the ATTAIN-MAINTAIN trial demonstrates orforglipron's effectiveness not just in initiating weight loss, but crucially, in sustaining it over time. This is a vital aspect of long-term obesity management, as weight regain is a common challenge for many individuals.

Orforglipron's Role in Weight Maintenance

The results from the ATTAIN-MAINTAIN trial are especially impactful for patients looking for flexible treatment options. Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average. This means that after losing weight on an injectable medication, individuals could transition to an oral pill and largely preserve their weight loss. This offers a practical and convenient solution for long-term weight management, potentially improving adherence and quality of life for patients who prefer an oral medication over ongoing injections. The ability to seamlessly switch therapies while maintaining benefits is a significant advancement.

Broader Implications for Treatment Landscape

The ongoing developments for orforglipron, particularly its regulatory submission and strong trial results, suggest it could become a cornerstone in the treatment of obesity. As an oral small-molecule GLP-1 receptor agonist, it represents a new generation of therapy that combines powerful efficacy with enhanced convenience. This could broaden access to effective weight management solutions, making it easier for more people to receive and adhere to treatment. If approved, orforglipron would provide a valuable alternative to existing injectable options, fulfilling a significant unmet need in the market.

What is the significance of oral GLP-1 medications?

Oral GLP-1 medications, like orforglipron, represent a significant advancement in the treatment of obesity and type 2 diabetes. Their importance stems primarily from the convenience they offer, which can dramatically impact patient adherence and access to effective care. This shift from injectable to oral administration has broad implications for how these chronic conditions are managed globally.

Convenience and Patient Adherence

The most immediate and obvious benefit of oral GLP-1 medications is their convenience. For many patients, taking a pill daily is a much simpler and more appealing option than administering weekly injections. This ease of use can lead to significantly improved patient adherence. When patients consistently take their medication as prescribed, they are more likely to achieve and maintain the desired health outcomes, whether that's weight loss or better blood sugar control. Injectable therapies, while highly effective, can be a barrier for individuals with needle aversion or those who find injections inconvenient to fit into their daily routines. Orforglipron, as a once-daily oral medication, directly addresses these concerns.

Expanding Access to Treatment

Oral GLP-1s have the potential to expand access to effective treatments for obesity and type 2 diabetes. The simplicity of an oral pill may make it easier for healthcare providers to prescribe and for patients to accept, particularly in settings where self-injection training or needle disposal can be logistical challenges. This wider accessibility can help more people benefit from GLP-1 receptor agonist therapy, which has proven efficacy in managing these conditions. By lowering the barrier to entry, oral options can democratize access to advanced metabolic treatments.

Small-Molecule Advantage

Orforglipron is specifically an oral small-molecule GLP-1 receptor agonist. This "small-molecule" designation is crucial because it means the drug can be absorbed intact through the digestive system. Many GLP-1 medications are large peptide molecules that would be broken down by stomach acids and digestive enzymes if taken orally, rendering them ineffective. Small molecules are structurally different, allowing them to bypass this degradation and enter the bloodstream to exert their therapeutic effects. This technological achievement is what makes a highly effective oral GLP-1 possible. A study on Orforglipron for obesity treatment was published in N Engl J Med. 2025 Nov 6, detailed by PMID: 40960239. This publication highlights the scientific validation of its small-molecule approach.

Potential Impact on the Healthcare System

The introduction of effective oral GLP-1s could also have a positive impact on the healthcare system. Easier administration might reduce the need for specific training sessions for injections, potentially freeing up healthcare resources. Furthermore, improved patient adherence due to convenience could lead to better long-term health outcomes, potentially reducing the incidence of diabetes-related complications and other obesity-related comorbidities. This, in turn, could lead to a reduction in overall healthcare costs associated with managing advanced disease states. The convenience and efficacy of oral GLP-1s are poised to transform the treatment landscape for millions.

Frequently Asked Questions

What is the main difference between retatrutide and orforglipron?

The main difference lies in their mechanism of action and administration. Retatrutide is an investigational triple agonist, targeting GLP-1, GIP, and glucagon receptors, and is currently being studied as an injectable medication. Orforglipron, on the other hand, is an oral small-molecule GLP-1 receptor agonist, meaning it's taken as a pill and primarily targets the GLP-1 receptor. Retatrutide showed significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes. Orforglipron delivered weight loss of up to an average of 27.3 lbs in one pivotal Phase 3 trial in adults with obesity.

Are these medications approved by the FDA yet?

Neither retatrutide nor orforglipron is currently approved by the FDA. Retatrutide is still in its Phase 3 clinical trial stage, with ongoing studies for obesity and overweight. Orforglipron has been submitted to the U.S. Food and Drug Administration for the treatment of obesity, meaning it is currently under review for potential approval. The FDA process involves a thorough evaluation of all clinical trial data to ensure both safety and efficacy before a drug can be made available to the public.

Can orforglipron replace injectable GLP-1s for weight loss maintenance?

Orforglipron has shown strong potential to replace injectable GLP-1s for weight loss maintenance. In the ATTAIN-MAINTAIN Phase 3 trial, participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average. This indicates that it can be an effective oral option for sustaining weight loss after initial treatment with injectable incretins. This flexibility could significantly improve long-term adherence and patient satisfaction.

What are the potential side effects of these new medications?

While specific detailed side effect profiles for retatrutide are still emerging from ongoing trials, orforglipron has shown a safety profile consistent with injectable GLP-1 medicines in its successful Phase 3 trials. Common side effects for GLP-1 class medications typically involve the gastrointestinal system, such as nausea, vomiting, diarrhea, and constipation. These are generally mild to moderate and often decrease over time as the body adjusts to the medication. As with any new drug, patients should discuss potential side effects with their healthcare provider.

Where can I find more information about Lilly's clinical trials?

You can find more detailed information about Lilly's clinical trials for retatrutide, orforglipron, and other investigational medications by visiting official clinical trial registries. For example, specific details about a study of retatrutide (LY3437943) in participants who have obesity or are overweight can be found by searching for NCT05929066 on ClinicalTrials.gov. Lilly also publishes news releases about trial results on its investor relations website, such as the announcement about retatrutide's significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes.